伊匹木单抗对比安慰剂在无症状或轻微症状的转移性去势抵抗性前列腺癌未接受化疗患者中的随机双盲III期试验
这项多中心双盲III期试验将无症状或轻微症状、未接受化疗且无内脏转移的转移性去势抵抗性前列腺癌患者按2:1随机分配至伊匹木单抗10 mg/kg组或安慰剂组。伊匹木单抗组中位总生存期为28.7个月,安慰剂组为29.7个月,风险比为1.11,差异无统计学意义。无进展生存期和前列腺特异性抗原缓解率在伊匹木单抗组较高,但免疫相关3至4级不良事件发生率也更高。
要点
- 伊匹木单抗组中位总生存期28.7个月,安慰剂组29.7个月,风险比1.11,无显著改善。
- 伊匹木单抗组中位无进展生存期5.6个月,安慰剂组3.8个月,风险比0.67。
- 伊匹木单抗组免疫相关3至4级不良事件发生率31%,安慰剂组2%。
核心结论
- 伊匹木单抗未改善转移性去势抵抗性前列腺癌患者的总生存期。
- 观察到的无进展生存期和前列腺特异性抗原缓解率提高提示在部分患者亚组中具有抗肿瘤活性。
研究设计与样本
- 多中心、双盲、III期随机对照试验。
- 无症状或轻微症状、未接受化疗且无内脏转移的转移性去势抵抗性前列腺癌患者按2:1随机分配至伊匹木单抗10 mg/kg组(400例随机,399例治疗)或安慰剂组(202例随机,199例治疗)。
- 伊匹木单抗10 mg/kg或安慰剂每3周给药一次,最多4次;未进展患者接受伊匹木单抗10 mg/kg或安慰剂维持治疗,每3个月一次。
- 主要终点为总生存期。
主要发现
- 伊匹木单抗组中位总生存期28.7个月(95% CI,24.5至32.5个月),安慰剂组29.7个月(95% CI,26.1至34.2个月),风险比1.11(95.87% CI,0.88至1.39;P=0.3667)。
- 伊匹木单抗组中位无进展生存期5.6个月,安慰剂组3.8个月,风险比0.67(95.87% CI,0.55至0.81)。
- 探索性分析显示,伊匹木单抗组前列腺特异性抗原缓解率23%,安慰剂组8%。
- 伊匹木单抗组中唯一在≥10%患者中报告的3至4级治疗相关不良事件为腹泻(15%)。
- 伊匹木单抗组有9例(2%)治疗相关不良事件导致的死亡;安慰剂组无死亡。
关键数值与推荐
- 伊匹木单抗10 mg/kg每3周一次,最多4次,随后每3个月维持治疗。
- 主要终点总生存期风险比1.11(95.87% CI,0.88至1.39;P=0.3667),未达统计学显著。
- 无进展生存期风险比0.67(95.87% CI,0.55至0.81)。
- 前列腺特异性抗原缓解率伊匹木单抗组23% vs 安慰剂组8%。
- 免疫相关3至4级不良事件发生率伊匹木单抗组31% vs 安慰剂组2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4. We evaluated treatment with ipilimumab in asymptomatic or minimally symptomatic patients with chemotherapy-naive metastatic castration-resistant prostate cancer without visceral metastases. Patients and Methods In this multicenter, double-blind, phase III trial, patients were randomly assigned (2:1) to ipilimumab 10 mg/kg or placebo every 3 weeks for up to four doses. Ipilimumab 10 mg/kg or placebo maintenance therapy was administered to nonprogressing patients every 3 months. The primary end point was overall survival (OS). Results Four hundred patients were randomly assigned to ipilimumab and 202 to placebo; 399 were treated with ipilimumab and 199 with placebo. Median OS was 28.7 months (95% CI, 24.5 to 32.5 months) in the ipilimumab arm versus 29.7 months (95% CI, 26.1 to 34.2 months) in the placebo arm (hazard ratio, 1.11; 95.87% CI, 0.88 to 1.39; P = .3667). Median progression-free survival was 5.6 months in the ipilimumab arm versus 3.8 with placebo arm (hazard ratio, 0.67; 95.87% CI, 0.55 to 0.81). Exploratory analyses showed a higher prostate-specific antigen response rate with ipilimumab (23%) than with placebo (8%). Diarrhea (15%) was the only grade 3 to 4 treatment-related adverse event (AE) reported in ≥ 10% of ipilimumab-treated patients. Nine (2%) deaths occurred in the ipilimumab arm due to treatment-related AEs; no deaths occurred in the placebo arm. Immune-related grade 3 to 4 AEs occurred in 31% and 2% of patients, respectively. Conclusion Ipilimumab did not improve OS in patients with metastatic castration-resistant prostate cancer. The observed increases in progression-free survival and prostate-specific antigen response rates suggest antitumor activity in a patient subset.
引用
- Beer TM, Kwon ED, Drake CG, et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol. 2016. PMID: 28034081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。